Which lipid parameter is most strongly correlated with ASCVD risk and is the primary target of statin therapy?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which lipid parameter is most strongly correlated with ASCVD risk and is the primary target of statin therapy?

The main concept tested is that LDL cholesterol is the primary lipid parameter linked to ASCVD risk and the main target of statin therapy. LDL-C is the cholesterol carried by LDL particles that deposit cholesterol into arterial walls, driving atherosclerosis. Genetic and clinical trial evidence show that lower LDL-C levels translate into fewer cardiovascular events, and statins reduce ASCVD risk mainly by lowering LDL-C through inhibition of hepatic cholesterol synthesis and upregulation of LDL receptors, which clears more LDL from the bloodstream. Triglycerides reflect another aspect of lipid biology and can indicate risk, especially in hypertriglyceridemia, but they are not as directly tied to ASCVD risk reduction with statin therapy as LDL-C. HDL cholesterol inversely correlates with risk in observational data, yet therapies that raise HDL-C have not consistently reduced ASCVD outcomes. Non-HDL cholesterol captures all atherogenic particles beyond LDL, and it becomes particularly useful when triglycerides are elevated, but LDL-C remains the strongest, most established target for reducing ASCVD risk with statins. So the lipid parameter most strongly correlated with ASCVD risk and the primary target of statin therapy is LDL cholesterol.

The main concept tested is that LDL cholesterol is the primary lipid parameter linked to ASCVD risk and the main target of statin therapy. LDL-C is the cholesterol carried by LDL particles that deposit cholesterol into arterial walls, driving atherosclerosis. Genetic and clinical trial evidence show that lower LDL-C levels translate into fewer cardiovascular events, and statins reduce ASCVD risk mainly by lowering LDL-C through inhibition of hepatic cholesterol synthesis and upregulation of LDL receptors, which clears more LDL from the bloodstream.

Triglycerides reflect another aspect of lipid biology and can indicate risk, especially in hypertriglyceridemia, but they are not as directly tied to ASCVD risk reduction with statin therapy as LDL-C. HDL cholesterol inversely correlates with risk in observational data, yet therapies that raise HDL-C have not consistently reduced ASCVD outcomes. Non-HDL cholesterol captures all atherogenic particles beyond LDL, and it becomes particularly useful when triglycerides are elevated, but LDL-C remains the strongest, most established target for reducing ASCVD risk with statins.

So the lipid parameter most strongly correlated with ASCVD risk and the primary target of statin therapy is LDL cholesterol.

More practice questions